Components of

Meningococcal Vaccines

Components Page
Excipients Table
Allergens Table
           
  Meningococcal conjugate vaccines Serogroup B meningococcal vaccines Polysaccharide
Name Menactra Menveo Bexsero Trumenba Menomune-A/C/Y/W-135
Manufacturer sanofi pasteur GlaxoSmithKline GlaxoSmithKline Pfizer/Wyeth sanofi pasteur
Viability Inactivated Inactivated Inactivated Inactivated Inactivated
Indicated Ages 9 months - 55 years 2 months - 55 years 10-25 years 10-25 years 2 years and older
Dose 0.5 mL 0.5 mL 0.5 mL 0.5 mL 0.5 mL
Schedule 9-23 months: 2 doses, 3 months apart
2-55 years: 1 dose
Booster for 15-55 at continued risk: 1 dose ≥4 years after prior dose
2 months: 2 doses at 2, 4, 6 and 12 months
7-23 months: 2 doses with dose 2 in second year of life and at least 3 months after first
2-55 years:1 dose
2 doses at least 1 month apart 3-dose schedule:at 0, 1-2 mos and 6 mos
2-dose schedule: at 0 and 6 months
Single dose
Route Intramuscular Intramuscular Intramuscular Intramuscular Subcutaneous
Appearance Clear to slightly turbid Clear and colorless White, opalescent Homogenous white Clear and colorless
Concentration • Meningococcal A, C, Y and W-135, 4 mcg each • MenA oligosaccharide, 10 mcg
• MenC, 5 mcg
• MenY, 5 mcg
• MenW-135 oligosaccharides, 5 mcg
• CRM197 protein, 32.7-64.1 mcg
• Neisserial adhesin A (NadA), 50 mcg
• Neisserial Heparin Binding Antigen (NHBA), 50 mcg
• Factor H binding protein (fHbp), 50 mcg
• Outer Membrane Vesicles (OMV), 25 mcg
• fHBP subfamily A, 60 mcg
• fHBP subfamily B, 60 mcg
• Menincococcal groups A, C, Y and W-135, 50 mcg from each serogroup
Preservative None None None None Mercury, 25 mcg in multidose vial
Adjuvant None None None None  
Excipients • Formaldehyde, <2.66 mcg • Formaldehyde, ≤0.30 mcg
• Yeast, amount not specified
• Amino acids, amount not specified
• Aluminum hydroxide (0.519 mg of Al3+), 1.5 mg
• Sodium chloride, 3.125 mg
• Histidine, 0.776 mg
• Sucrose, 10 mg
• Kanamycin, 0.01 mcg
• Polysorbate 80, 0.018 mg
• Al3+ (as AlPO4), 0.25mg
• Lactose, 2.5-5 mb
Allergens • Neomycin, ≤0.02 mcg
• Residual egg proteins, <0.4 mcg
• Latex, tip caps of the prefilled syringes contain natural rubber latex
• None • Latex, tip caps of the prefilled syringes contain natural rubber latex • None • Latex, tip caps of the prefilled syringes contain natural rubber latex
Media N meningitidis A, C, Y and W-135 strains
• Cultured on Mueller Hinton agar
• Grown in Watson Scherp

Corynebacterium diphtheriae
• Grown in modified culture medium containing hydrolyzed casein
• Detoxified using formaldehyde

Diphtheria toxoid protein
• Purified by ammonium sulfate fractionation and diafiltration
N meningitidis A, C, Y and W-135 strains
• Cultured and grown in Franz Complete medium and treated with formaldehyde

Corynebacterium diphtheriae
• Cultured and grown on CY medium containing yeast extracts and amino acids

Protein carrier (CRM197)
• Produced by bacterial fermentation
• Purified by a series of chromatography and ultrafiltration steps
  • Fermentation growth media N meningitidis
• Cultivated on Mueller Hinton casein agar and grown in Watson Scherp casamino acid media
• Purified polysaccharide extracted and separated from the media by procedures which include centrifugation, detergent precipitation, alcohol precipitation, solvent or organic extraction, and diafiltration
Packaging 5-pack of single-dose vials Five-dose package of 5 vials MenA component and 5 vials MenCYW-135 component Single pre-filled syringe and 10-pack Single pre-filled syringe and 5-pack Single-dose vial with vial of diluent
10-dose vial with vial of diluent
Storage 2 to 8 C (36-46 F)
Do not freeze
2 to 8 C (36-46 F)
Do not freeze
2 to 8 C (36-46 F)
Do not freeze
2 to 8 C (36-46 F)
Do not freeze
2 to 8 C (36-46 F)
Do not freeze
PI date September 2016 March 2017 October 2017 September 2017 April 2013
          table last updated 10/24/17